Compare ASRV & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASRV | TENX |
|---|---|---|
| Founded | 1983 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.4M | 71.1M |
| IPO Year | 1994 | 2001 |
| Metric | ASRV | TENX |
|---|---|---|
| Price | $4.86 | $2.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | 18.4K | ★ 10.4M |
| Earning Date | 04-21-2026 | 05-15-2026 |
| Dividend Yield | ★ 3.16% | N/A |
| EPS Growth | ★ 61.90 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $14,634,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.74 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.80 | $1.31 |
| 52 Week High | $5.38 | $19.40 |
| Indicator | ASRV | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 48.31 | 25.48 |
| Support Level | $3.62 | $1.31 |
| Resistance Level | $5.10 | $2.43 |
| Average True Range (ATR) | 0.26 | 0.19 |
| MACD | -0.05 | 0.44 |
| Stochastic Oscillator | 35.23 | 43.87 |
AmeriServ Financial Inc is a bank holding company. The company and its subsidiaries derive substantially all of their income from banking, bank-related services, and trust-related services. Its operating segment includes community banking and it generates maximum revenue. The community banking segment includes both retail and commercial banking activities. The company also offers retail banking which includes the deposit-gathering branch franchise and lending to both individuals and small businesses; Lending activities include residential mortgage loans, direct consumer loans, and small business commercial loans; Commercial banking to businesses includes commercial loans, business services, and CRE loans.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.